Research News and Research

RSS

WellPoint executive defends premium increases at congressional hearing

In a congressional hearing Wednesday, an insurance company executive justified proposed premium increases and warned "that pending legislation" could make the problem of high medical costs worse. "The executive, Angela F. Braly, president of WellPoint, made the comments in testimony prepared for a hearing of the House Energy and Commerce Committee," The New York Times reports.

25 Feb 2010

Patented chemical derived from sugar may be an alternative for BPA

Michael Jaffe, a professor of biomedical engineering at NJIT, has received a patent for a chemical derived from sugar. This new material is a derivative of isosorbide and may be able to replace bisphenol A (BPA) in a number of consumer products, including the lining of tin cans.

25 Feb 2010

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail Corporation today announced financial results for the three-month and 12-month periods ending December 31, 2009.

25 Feb 2010

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Impax Laboratories, Inc. today reported its strongest financial results in its history due to record sales from its Global products sales channel.

25 Feb 2010

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Labopharm Inc. today reported its financial results for the fourth quarter and fiscal year ended December 31, 2009. All figures are in Canadian dollars unless otherwise stated.

25 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Campaign to stop sale of electronic mosquito repellents by major airlines begins to bear fruit

A campaign to stop the sale of electronic mosquito repellents by major airlines is beginning to bear fruit with the immediate withdrawal of the products from KLM flights. The issue being that these electronic repellents, sold to airline passengers, many on their way to malaria endemic countries, just don't work.

25 Feb 2010

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

Adolor Corporation today reported a net loss of $47.9 million, or $(1.03) per basic and diluted share, for the year ended December 31, 2009, compared to a net loss of $30.1 million, or $(0.65) per basic and diluted share, for the year ended December 31, 2008.

25 Feb 2010

"Hope – It's In Our Genes" rare disease campaign slogan translated into multiple international languages and Braille

The Global Genes Project (www.globalgenesproject.org), today announced that its rare disease campaign slogan, "Hope – It's In Our Genes™," has been translated into multiple international languages and Braille by rare disease patient advocates and supporters from around the world. The translation of this slogan unifies the rare disease community and global network under one banner.

25 Feb 2010

First Edition: February 25, 2010

Today's news is all about today's White House health summit -- with highlights of how WellPoint got grilled about proposed premium rate increases during a congressional hearing and how the House voted to repeal insurers' antitrust exemption.

25 Feb 2010

Mylan reports total revenues of $1.35 billion for fourth-quarter 2009

Mylan Inc. today announced its financial results for the three and twelve months ended December 31, 2009.

25 Feb 2010

Greater access to rehabilitation after TIA needed to prevent future strokes

Transient Ischemic Attacks (TIA) are often called "mini strokes" for good reasons -- the short-term symptoms can mimic a stroke and up to 10 percent of first-time sufferers often experience full-blown strokes within as little as 90 days. Despite the well-known statistics, no post-TIA regimen exists to help prevent future strokes -- but this might be changing.

25 Feb 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

CHOP and AIAM collaborate to develop more accurate child crash test dummies

A research report released today by The Children's Hospital of Philadelphia (CHOP) and the Association of International Automobile Manufacturers, Inc. (AIAM) details CHOP's cutting-edge work with academic and industry collaborators to develop more accurate child crash test dummies, called child anthropometric test devices (ATD's).

25 Feb 2010

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

IOS Press is pleased to announce the 20th anniversary of the peer-reviewed journal Restorative Neurology and Neuroscience. Since founded in 1989 by pioneering neuroscientist Donald G. Stein, RNN has focused on the emerging field of brain plasticity, repair and rehabilitation and has published not only numerous original scientific publications, but also review papers in basic research (animal experiments, in vitro studies) and in the clinical sciences.

25 Feb 2010

Cannabis Science completes selection of initial cannabis-based pharmaceutical for FDA clinical trials

Cannabis Science Inc., a pharmaceutical cannabis company, is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials. Based on extensive studies, the Company has decided to contract with a group based in Colorado to handle the Company’s FDA filings.

25 Feb 2010

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.

25 Feb 2010

The Coalition for Evidence-Based Policy selects Botvin LST as "Top Tier" program

Botvin LifeSkills Training has been selected as a "Top Tier" program by The Coalition for Evidence-Based Policy. The Top Tier initiative, which is being followed closely by Congress, focuses on identifying and validating social programs meeting the highest standard of evidence of effectiveness.

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

Caliper Life Sciences files patent infringement lawsuit against Carestream Health

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, and its wholly owned subsidiary Xenogen Corporation, today announced the filing of a patent infringement lawsuit in the U.S. District Court for the Eastern District of Texas.

25 Feb 2010

Research News and Research

WellPoint executive defends premium increases at congressional hearing

Patented chemical derived from sugar may be an alternative for BPA

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Impax Laboratories announces record net income of $0.61 per diluted share for fourth-quarter 2009

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Campaign to stop sale of electronic mosquito repellents by major airlines begins to bear fruit

Adolor announces $14.6M net product sales of ENTEREG for year ended December 31, 2009

"Hope – It's In Our Genes" rare disease campaign slogan translated into multiple international languages and Braille

First Edition: February 25, 2010

Mylan reports total revenues of $1.35 billion for fourth-quarter 2009

Greater access to rehabilitation after TIA needed to prevent future strokes

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

CHOP and AIAM collaborate to develop more accurate child crash test dummies

IOS Press announces the 20th anniversary of Restorative Neurology and Neuroscience journal

Cannabis Science completes selection of initial cannabis-based pharmaceutical for FDA clinical trials

Texas Plant-Expressed Vaccine Consortium announces biotherapeutic manufacturing initiative for infectious diseases

The Coalition for Evidence-Based Policy selects Botvin LST as "Top Tier" program

Study demonstrates Prochymal treamtent is safe for cardiac patients

Caliper Life Sciences files patent infringement lawsuit against Carestream Health

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence